Dec 7, 2020
Bob Hutchens, President and CEO, StemBioSys talks about their work building a set of tools that are being used around the world by pharmaceutical companies in early-stage drug discovery. CELLvo and CELLvo Matrix Plus are technologies that grow cells from amniotic fluid from natural births and reverse-engineer them into pluripotent stem cells. Overcoming challenges of turning these cells into cardiomyocyte cells researchers are able to more quickly and accurately determine drug safety on mature adult cardiomyocyte. This technology can produce more accurate readings than animal models and more quickly produce cells that are a strong predictor of drug efficacy and drug safety.
@StemBioSys #StemBioSys #CellvoMatrixPlus #DrugToxicityScreening #Stemcells